➀ MIT researchers developed bottlebrush-shaped polymer particles (ABCs) to deliver hundreds of chemotherapy drugs directly to tumors via antibody targeting, significantly increasing payload capacity compared to traditional antibody-drug conjugates (ADCs);

➁ In mouse models of breast and ovarian cancer, ABCs eradicated most tumors at doses 100 times lower than conventional drugs and outperformed FDA-approved ADCs like T-DXd and TDM-1;

➂ The technology allows customizable drug combinations, including less potent agents and experimental therapies like PROTACs, with potential applications across cancer types by swapping targeting antibodies.